PRQR - ProQR Therapeutics N.V.
IEX Last Trade
2.7
-0.010 -0.370%
Share volume: 7,634
Last Updated: Thu 26 Dec 2024 08:29:59 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$2.71
-0.01
-0.37%
Fundamental analysis
24%
Profitability
25%
Dept financing
5%
Liquidity
50%
Performance
21%
Performance
5 Days
0 0%
1 Month
-22.38%
3 Months
50.00%
6 Months
61.82%
1 Year
32.84%
2 Year
-1.48%
Key data
Stock price
$2.70
DAY RANGE
$2.62 - $2.72
52 WEEK RANGE
$1.66 - $4.62
52 WEEK CHANGE
$35.53
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/14/2024
Company detail
CEO: Daniel Anton de Boer
Region: US
Website: proqr.com
Employees: 180
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: proqr.com
Employees: 180
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
ProQR Therapeutics N.V. engages in the discovery and development of RNA-based therapeutics. It is primarily developing sepofarsen that is in phase II/III illuminate trial for treating leber's congenital amaurosis 10 disease. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University.
Recent news